CTOs on the Move

Keros Therapeutics

www.kerostx.com

 
Keros Therapeutics is dedicated to the discovery and development of novel therapeutics for neuromuscular diseases
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million
  • www.kerostx.com
  • 99 Hayden Avenue
    Lexington, MA USA 02421
  • Phone: 617.314.6297

Executives

Name Title Contact Details

Funding

Keros Therapeutics raised $23M on 01/08/2019
Keros Therapeutics raised $56M on 03/04/2020

Similar Companies

Mavupharma

Mavupharma is developing non-nucleotide, conditional modulators of the STING pathway to treat cancer and infectious disease.

Therics Inc

Therics Inc is a Princeton, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Zynerba

Zynerba (NASDAQ: ZYNE) is dedicated to improving the lives of people with rare and near rare neuropsychiatric disorders where there is a high unmet medical need by pioneering the development and commercialization of next-generation pharmaceutically-produced cannabinoid therapeutics formulated for transdermal delivery. Cannabinoids interact with specific receptors throughout the body to produce pharmacologic effects, primarily in the CNS and immune systems. Transdermal delivery has the potential to reduce adverse effects associated with oral dosing because it allows the drug to be absorbed through the skin directly into the bloodstream, avoiding the gastrointestinal tract and lessening the opportunity for GI-related adverse events. It also avoids first-pass liver metabolism, potentially enabling lower dosage levels of active pharmaceutical ingredients with a higher bioavailability and an improved safety profile. Zynerba`s lead patent-protected product candidate in clinical development is ZYN002: ZYN002 is the first and only pharmaceutically-produced cannabidiol (CBD) formulated as a permeation-enhanced gel for transdermal delivery. Through a proprietary combination of our pharmaceutically-produced CBD and permeation enhancers, we believe we can effectively deliver CBD through the layers of the epidermis and into the circulatory system. The company is currently assessing ZYN002 in Fragile X syndrome and certain adult and pediatric refractory epilepsies. These include adult refractory focal epilepsy and developmental and epileptic encephalopathies (DEE), a heterogeneous group of rare and ultra-rare epilepsy syndromes associated with severe cognitive impairment and behavioral disturbances.

Total Repair Express

Total Repair Express is a Hillsborough, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Celtaxsys

Celtaxsys is a privately-held clinical stage drug discovery and development company with operations in San Francisco, CA and Atlanta, GA.